What is EnteroBiotix?
EnteroBiotix is a clinical-stage biopharmaceutical company dedicated to establishing a leading position in the field of full-spectrum microbiome therapeutics. The company's flagship product, EBX-102-02, is poised to be the first therapy to modify the disease course for irritable bowel syndrome. Following encouraging results from its Phase 2a trial (TrIuMPH), the therapy is now advancing into Phase 2b development through the RISE trial, signaling a critical juncture in its clinical journey. The company's focus on addressing unmet needs in gastrointestinal health positions it within a rapidly growing and scientifically dynamic sector.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $91.6M across 7 funding rounds:
Angel/Seed
$4M
Series A
$21.5M
Debt
$14.6M
Private Equity
$19.8M
Private Equity
$1.4M
Private Equity
$5.3M
Unspecified
$25M
Angel/Seed (2019): $4M with participation from Scottish Enterprise, SIS Ventures, Barwell, University of Aberdeen, Bank Workers Charity, Equity Gap, NCIMB, Syndicate Room, Fund Twenty8, and Gabriel
Series A (2021): $21.5M led by Scottish Enterprise, SIS Ventures, Kineticos Ventures, and Thairm Bio
Debt (2024): $14.6M supported by Scottish National Investment Bank
Private Equity (2024): $19.8M featuring Kineticos
Private Equity (2025): $1.4M, investors not publicly disclosed
Private Equity (2026): $5.3M, investors not publicly disclosed
Unspecified (2026): $25M led by Scottish National Investment Bank
Key Investors in EnteroBiotix
Scottish National Investment Bank
The Scottish National Investment Bank is a development investment bank focused on providing long-term capital for businesses and projects across Scotland, aiming to foster a fairer and more sustainable economy through impactful investments in climate change, community transformation, and innovation.
Scottish Enterprise
Scottish Enterprise is Scotland's national economic development agency, established to support businesses and drive economic growth across the country. It focuses on innovation, internationalization, and investment to create jobs and improve Scotland's competitiveness.
Kineticos
Kineticos is a management consulting firm specializing in the life science industry, offering expertise in corporate strategy, sales and marketing, operational execution, and technology and innovation services to support client growth and development.
What's next for EnteroBiotix?
With the recent influx of major strategic capital, EnteroBiotix is well-positioned to accelerate its clinical development pipeline, particularly for its lead candidate EBX-102-02. The company's progression into Phase 2b trials signifies a move towards scaling its operations and further validating its therapeutic approach. Future investment will likely focus on completing these trials, navigating regulatory pathways, and preparing for potential commercialization. The company's commitment to advancing microbiome therapeutics suggests a strategic focus on innovation and addressing significant patient needs within the biopharmaceutical industry.
See full EnteroBiotix company page
